Filtered By:
Specialty: Lipidology
Condition: Heart Attack

This page shows you your search results in order of date.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Admission LDL-cholesterol, statin pretreatment and early outcomes in acute ischemic stroke
Elevated LDL-cholesterol (LDL-C) levels increase the risk of stroke and vascular events. Initiation and maintenance of lipid-lowering therapy after acute ischemic stroke (AIS) appears to be guided by LDL-C levels.1 The EUROASPIRE III stroke-specific module shows that secondary prevention and risk factor control in patients after ischemic stroke need to be improved since about half of patients are not achieving target lipid levels defined in European guidelines.2 However, lower levels of LDL-C are paradoxically associated with increased mortality in ST elevation myocardial infarction patients.
Source: Journal of Clinical Lipidology - August 7, 2023 Category: Lipidology Authors: Joon-Tae Kim, Ji Sung Lee, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyungbok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung Tags: Original Research Source Type: research

Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease
Elevated lipoprotein(a) [Lp(a)] is an atherogenic, cholesterol-containing, genetically-determined, independent risk factor for ischemic cardiovascular disease outcomes. In clinical settings, elevated serum Lp(a) predicts increased myocardial infarction, stroke, peripheral arterial disease, and aortic valve stenosis risk. Knowledge of a patient's Lp(a) may modify management, including a lower low-density lipoprotein cholesterol (LDL-C) goal and consideration of using a PCSK9 inhibitor.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Bhavana Upadhyaya, Robert C. Block, Ying Wang, Jeffrey T. Bruckel Tags: Epidemiology of Cardiovascular Disease Source Type: research

Trends in Lipoprotein(a) Testing at the University of Pennsylvania Health Systems from 2012-2021
Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are associated with a higher risk for myocardial infarction, coronary artery disease, aortic stenosis, and stroke. Lp(a) levels are primarily genetically driven and minimally impacted by diet and lifestyle, so a single measurement can identify individuals with elevated levels. However, Lp(a) screening has not been widely integrated into clinical practice in the United States.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Archna Bajaj, Lakshmi Parvathinathan, Marjorie Risman, Ahmad Alsattari, Daniel J. Rader Tags: Best Practices in Lipid Management Source Type: research

Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention.
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - August 28, 2022 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Source Type: research

High lipoprotein(a) levels predict severity of coronary artery disease in patients hospitalized for acute myocardial infarction. Data from the French RICO survey
Lipoprotein(a) (Lp(a)) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction (MI), ischemic stroke and peripheral artery disease, as well as for calcific aortic valve stenosis1-4. Lp(a) contributes to ASCVD risk via multiple mechanisms broadly classified in three categories, proatherogenic, proinflammatory, and potentially antifibrinolytic2. Epidemiological studies, including meta-analyses5,6, and genetic studies, strongly support a causal association between high levels of Lp(a) and increased risk of ASCVD.
Source: Journal of Clinical Lipidology - July 17, 2022 Category: Lipidology Authors: Michel Farnier, Fr édéric Chagué, Maud Maza, Florence Bichat, David Masson, Yves Cottin, Marianne Zeller Source Type: research

Triglyceride-lowering and Anti-inflammatory Mechanisms of Omega-3 Polyunsaturated Fatty Acids for Atherosclerotic Cardiovascular Risk Reduction
Atherosclerotic cardiovascular disease (ASCVD) is defined as acute coronary syndrome, stable angina, history of myocardial infarction, coronary or other arterial revascularization, ischemic stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin.1 Despite continuous advances in medical intervention and surgical therapy for the treatment of ASCVD, the latter remains the leading cause of morbidity and mortality globally. In the United States, nearly 808,000 people died of ASCVD in 2014, translating to about 1 of every 3 deaths,2 and the death rate from ASCVD rose in 2015 by ...
Source: Journal of Clinical Lipidology - June 5, 2021 Category: Lipidology Authors: Qiyuan Keith Liu Tags: Review Article Source Type: research

Lipoprotein(a) Levels and Association with Myocardial Infarction and Stroke in a Nationally Representative Cross-Sectional US Cohort
Lipoprotein(a) (Lp(a)) has not been well-studied in a nationally representative US cohort.
Source: Journal of Clinical Lipidology - July 2, 2020 Category: Lipidology Authors: Eric J. Brandt, Arya Mani, Erica S. Spatz, Nihar Desai, Khurram Nasir Tags: Original Research Source Type: research

Association of sleep duration with stroke, myocardial infarction, and tumors in a Chinese population with metabolic syndrome: a retrospective study
Previous studies have suggested that abnormal sleep duration is associated with increased risk of metabolic syndrome (MetS). However, evidence on the association of sleep duration with stroke, myocardial infar...
Source: Lipids in Health and Disease - June 27, 2020 Category: Lipidology Authors: Yingnan YE, Linxi ZHANG, Anping WANG, Yuxia Wang, Shiqing WANG, Guang NING and Yiming MU Tags: Research Source Type: research

Response to: “Arrhythmia paradox in patients with familial hypercholesterolemia”
We read the letter by Mirzaee and Cameron with great interest. We recently assessed the prognostic impact of clinically diagnosed familial hypercholesterolemia (FH) on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention for chronic and acute coronary syndromes. In our cohort, patients with probable or definite FH according to the Dutch Lipid Clinic Network faced a significant, approximate 2-fold increased risk for subsequent atherothrombotic events (death, myocardial infarction, or stroke) during a 6-year period of follow-up compared with patients with possible or unlikely FH.
Source: Journal of Clinical Lipidology - December 23, 2019 Category: Lipidology Authors: Maximilian Tscharre, Kurt Huber Tags: Letter to Editor Source Type: research

Lipid management in people with peripheral artery disease
Purpose of review To summarize recent data on the role of dyslipidaemia and the benefit from managing this in people with disease of the abdominal aorta and its peripheral branches (peripheral artery disease, PAD). Recent findings Findings from the Further Cardiovascular Outcomes Research with Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibition in Subjects with Elevated Risk (FOURIER) trial demonstrate the benefit of intensely lowering low-density lipoprotein-cholesterol (LDL-c) in people with PAD to substantially reduce the incidence of major cardiovascular events (MACE; myocardial infarction, stroke or ...
Source: Current Opinion in Lipidology - November 5, 2019 Category: Lipidology Tags: THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts Source Type: research

Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D Patient-Oriented and Epidemiological Research
APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs; based on qualitative apolipoprotein complement) have been associated with dyslipidemia and CVD. Our main objective was to define associations of serum apolipoproteins and ADLSs with "any CVD" and "major atherosclerotic cardiovascular events" (MACEs) in a prospective study of T1D. Serum apolipoproteins and ADLSs (14 biomarkers in total) were measured in sera (obtained between 1997 and 2000) from a subset (n = 465) of the Epidemiology of Diabetes Interventions and Complications cohort. Prospective associations of "any CVD" (myocardial infarction,...
Source: The Journal of Lipid Research - July 31, 2019 Category: Lipidology Authors: Basu, A., Bebu, I., Jenkins, A. J., Stoner, J. A., Zhang, Y., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., Budoff, M. J., Alaupovic, P., Lyons, T. J., the Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Rese Tags: Patient-Oriented and Epidemiological Research Source Type: research

Survey of the Erythrocyte EPA+DHA Levels in the Heart Attack/Stroke Belt
ConclusionsIndividuals in the CVD “belt” had relatively low O3I levels. Since in other settings, a low O3I is associated with increased risk for CVD, this may be one factor contributing to the higher risk for CVD in this region of the US.
Source: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) - July 14, 2019 Category: Lipidology Source Type: research

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come —A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - May 16, 2019 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Tags: Original Research Source Type: research

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease –related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform trea...
Source: Journal of Clinical Lipidology - May 16, 2019 Category: Lipidology Authors: Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, B ørge G. Nordestgaard, Carl E. Orringer Tags: Original Research Source Type: research